MovDisordV3, Main, Exploration, bibRecord, 003D87

Cardiovascular effects of methamphetamine in Parkinson's disease patients

Identifieur interne : 003D87 ( Main/Exploration ); précédent : 003D86; suivant : 003D88

Cardiovascular effects of methamphetamine in Parkinson's disease patients

Auteurs : Nicola Pavese [Royaume-Uni] ; Ornella Rimoldi [Royaume-Uni] ; Alexander Gerhard [Royaume-Uni] ; David J. Brooks [Royaume-Uni] ; Paola Piccini [Royaume-Uni]

Source :

Movement Disorders [ 0885-3185 ] ; 2004-03.

RBID : ISTEX:8EF174553A1B0790F23828A592A337B690E045A8

Descripteurs français

Pascal (Inist)
- Homme, Parkinson maladie, Système nerveux pathologie.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Adrenergic Fibers (drug effects), Analysis of Variance, Blood Pressure (drug effects), Brain (drug effects), Catecholamines (antagonists & inhibitors), Dopamine Agents (administration & dosage), Dopamine Agents (adverse effects), Dopamine Agents (therapeutic use), Drug Therapy, Combination, Electrocardiography (drug effects), Female, Heart Rate (drug effects), Human, Humans, Injections, Intravenous, Levodopa (therapeutic use), Male, Methamphetamine (administration & dosage), Methamphetamine (adverse effects), Methamphetamine (therapeutic use), Middle Aged, Myocardium (metabolism), Nervous system diseases, Parkinson Disease (drug therapy), Parkinson disease, Parkinson's disease, Presynaptic Terminals (drug effects), Psychomotor Agitation (etiology), Tomography, Emission-Computed, blood pressure, methamphetamine, postganglionic sympathetic neurons.
MESH :
- chemical , administration & dosage : Dopamine Agents, Methamphetamine.
- chemical , adverse effects : Dopamine Agents, Methamphetamine.
- chemical , antagonists & inhibitors : Catecholamines.
- drug effects : Adrenergic Fibers, Blood Pressure, Brain, Electrocardiography, Heart Rate, Presynaptic Terminals.
- drug therapy : Parkinson Disease.
- etiology : Psychomotor Agitation.
- metabolism : Myocardium.
- chemical , therapeutic use : Dopamine Agents, Levodopa, Methamphetamine.
- Analysis of Variance, Drug Therapy, Combination, Female, Humans, Injections, Intravenous, Male, Middle Aged, Tomography, Emission-Computed.

Abstract

Cardiovascular responses after intravenous methamphetamine were assessed in 11 Parkinson's disease (PD) patients. Systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate (HR), and electrocardiogram (ECG) were monitored for 103 minutes. After methamphetamine administration, SBP and DBP increased significantly in both PD and normal controls whereas placebo had no effect. In PD patients, however, the duration of SBP and DBP responses to methamphetamine and the maximum increase from baseline was attenuated compared with the controls. A significant correlation was found between individual BP responsiveness and the Unified Parkinson's Disease Rating Scale (UPDRS) motor score. These findings suggest that in PD there is impairment of catecholamine release from peripheral sympathetic presynaptic terminals, which correlates with motor impairment. © 2003 Movement Disorder Society

Url:

https://api.istex.fr/document/8EF174553A1B0790F23828A592A337B690E045A8/fulltext/pdf

DOI: 10.1002/mds.10651

Affiliations:

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cardiovascular effects of methamphetamine in Parkinson's disease patients</title>
<author><name sortKey="Pavese, Nicola" sort="Pavese, Nicola" uniqKey="Pavese N" first="Nicola" last="Pavese">Nicola Pavese</name>
</author>
<author><name sortKey="Rimoldi, Ornella" sort="Rimoldi, Ornella" uniqKey="Rimoldi O" first="Ornella" last="Rimoldi">Ornella Rimoldi</name>
</author>
<author><name sortKey="Gerhard, Alexander" sort="Gerhard, Alexander" uniqKey="Gerhard A" first="Alexander" last="Gerhard">Alexander Gerhard</name>
</author>
<author><name sortKey="Brooks, David J" sort="Brooks, David J" uniqKey="Brooks D" first="David J." last="Brooks">David J. Brooks</name>
</author>
<author><name sortKey="Piccini, Paola" sort="Piccini, Paola" uniqKey="Piccini P" first="Paola" last="Piccini">Paola Piccini</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:8EF174553A1B0790F23828A592A337B690E045A8</idno>
<date when="2004" year="2004">2004</date>
<idno type="doi">10.1002/mds.10651</idno>
<idno type="url">https://api.istex.fr/document/8EF174553A1B0790F23828A592A337B690E045A8/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001227</idno>
<idno type="wicri:Area/Istex/Curation">001227</idno>
<idno type="wicri:Area/Istex/Checkpoint">002768</idno>
<idno type="wicri:doubleKey">0885-3185:2004:Pavese N:cardiovascular:effects:of</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:15022183</idno>
<idno type="wicri:Area/PubMed/Corpus">003533</idno>
<idno type="wicri:Area/PubMed/Curation">003533</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003535</idno>
<idno type="wicri:Area/Ncbi/Merge">000D51</idno>
<idno type="wicri:Area/Ncbi/Curation">000D51</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000D51</idno>
<idno type="wicri:doubleKey">0885-3185:2004:Pavese N:cardiovascular:effects:of</idno>
<idno type="wicri:Area/Main/Merge">005745</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:04-0223972</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002262</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000A59</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">002220</idno>
<idno type="wicri:doubleKey">0885-3185:2004:Pavese N:cardiovascular:effects:of</idno>
<idno type="wicri:Area/Main/Merge">005A58</idno>
<idno type="wicri:Area/Main/Curation">003D87</idno>
<idno type="wicri:Area/Main/Exploration">003D87</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Cardiovascular effects of methamphetamine in Parkinson's disease patients</title>
<author><name sortKey="Pavese, Nicola" sort="Pavese, Nicola" uniqKey="Pavese N" first="Nicola" last="Pavese">Nicola Pavese</name>
<affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>MRC Clinical Science Center and Division of Neurosciences, Faculty of Medicine, Imperial College. Hammersmith Hospital Campus, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Rimoldi, Ornella" sort="Rimoldi, Ornella" uniqKey="Rimoldi O" first="Ornella" last="Rimoldi">Ornella Rimoldi</name>
<affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>MRC Clinical Science Center and Division of Neurosciences, Faculty of Medicine, Imperial College. Hammersmith Hospital Campus, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Gerhard, Alexander" sort="Gerhard, Alexander" uniqKey="Gerhard A" first="Alexander" last="Gerhard">Alexander Gerhard</name>
<affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>MRC Clinical Science Center and Division of Neurosciences, Faculty of Medicine, Imperial College. Hammersmith Hospital Campus, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Brooks, David J" sort="Brooks, David J" uniqKey="Brooks D" first="David J." last="Brooks">David J. Brooks</name>
<affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>MRC Clinical Science Center and Division of Neurosciences, Faculty of Medicine, Imperial College. Hammersmith Hospital Campus, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Piccini, Paola" sort="Piccini, Paola" uniqKey="Piccini P" first="Paola" last="Piccini">Paola Piccini</name>
<affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>MRC Clinical Science Center and Division of Neurosciences, Faculty of Medicine, Imperial College. Hammersmith Hospital Campus, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2004-03">2004-03</date>
<biblScope unit="vol">19</biblScope>
<biblScope unit="issue">3</biblScope>
<biblScope unit="page" from="298">298</biblScope>
<biblScope unit="page" to="303">303</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">8EF174553A1B0790F23828A592A337B690E045A8</idno>
<idno type="DOI">10.1002/mds.10651</idno>
<idno type="ArticleID">MDS10651</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adrenergic Fibers (drug effects)</term>
<term>Analysis of Variance</term>
<term>Blood Pressure (drug effects)</term>
<term>Brain (drug effects)</term>
<term>Catecholamines (antagonists & inhibitors)</term>
<term>Dopamine Agents (administration & dosage)</term>
<term>Dopamine Agents (adverse effects)</term>
<term>Dopamine Agents (therapeutic use)</term>
<term>Drug Therapy, Combination</term>
<term>Electrocardiography (drug effects)</term>
<term>Female</term>
<term>Heart Rate (drug effects)</term>
<term>Human</term>
<term>Humans</term>
<term>Injections, Intravenous</term>
<term>Levodopa (therapeutic use)</term>
<term>Male</term>
<term>Methamphetamine (administration & dosage)</term>
<term>Methamphetamine (adverse effects)</term>
<term>Methamphetamine (therapeutic use)</term>
<term>Middle Aged</term>
<term>Myocardium (metabolism)</term>
<term>Nervous system diseases</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson disease</term>
<term>Parkinson's disease</term>
<term>Presynaptic Terminals (drug effects)</term>
<term>Psychomotor Agitation (etiology)</term>
<term>Tomography, Emission-Computed</term>
<term>blood pressure</term>
<term>methamphetamine</term>
<term>postganglionic sympathetic neurons</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Dopamine Agents</term>
<term>Methamphetamine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Dopamine Agents</term>
<term>Methamphetamine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Catecholamines</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Adrenergic Fibers</term>
<term>Blood Pressure</term>
<term>Brain</term>
<term>Electrocardiography</term>
<term>Heart Rate</term>
<term>Presynaptic Terminals</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Psychomotor Agitation</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Myocardium</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Dopamine Agents</term>
<term>Levodopa</term>
<term>Methamphetamine</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Analysis of Variance</term>
<term>Drug Therapy, Combination</term>
<term>Female</term>
<term>Humans</term>
<term>Injections, Intravenous</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Tomography, Emission-Computed</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Homme</term>
<term>Parkinson maladie</term>
<term>Système nerveux pathologie</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Cardiovascular responses after intravenous methamphetamine were assessed in 11 Parkinson's disease (PD) patients. Systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate (HR), and electrocardiogram (ECG) were monitored for 103 minutes. After methamphetamine administration, SBP and DBP increased significantly in both PD and normal controls whereas placebo had no effect. In PD patients, however, the duration of SBP and DBP responses to methamphetamine and the maximum increase from baseline was attenuated compared with the controls. A significant correlation was found between individual BP responsiveness and the Unified Parkinson's Disease Rating Scale (UPDRS) motor score. These findings suggest that in PD there is impairment of catecholamine release from peripheral sympathetic presynaptic terminals, which correlates with motor impairment. © 2003 Movement Disorder Society</div>
</front>
</TEI>
<affiliations><list><country><li>Royaume-Uni</li>
</country>
<region><li>Angleterre</li>
<li>Grand Londres</li>
</region>
<settlement><li>Londres</li>
</settlement>
</list>
<tree><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Pavese, Nicola" sort="Pavese, Nicola" uniqKey="Pavese N" first="Nicola" last="Pavese">Nicola Pavese</name>
</region>
<name sortKey="Brooks, David J" sort="Brooks, David J" uniqKey="Brooks D" first="David J." last="Brooks">David J. Brooks</name>
<name sortKey="Gerhard, Alexander" sort="Gerhard, Alexander" uniqKey="Gerhard A" first="Alexander" last="Gerhard">Alexander Gerhard</name>
<name sortKey="Piccini, Paola" sort="Piccini, Paola" uniqKey="Piccini P" first="Paola" last="Piccini">Paola Piccini</name>
<name sortKey="Rimoldi, Ornella" sort="Rimoldi, Ornella" uniqKey="Rimoldi O" first="Ornella" last="Rimoldi">Ornella Rimoldi</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003D87 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003D87 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:8EF174553A1B0790F23828A592A337B690E045A8
   |texte=   Cardiovascular effects of methamphetamine in Parkinson's disease patients
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

Cardiovascular effects of methamphetamine in Parkinson's disease patients

Cardiovascular effects of methamphetamine in Parkinson's disease patients

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.